Publications by authors named "Steven Knapper"

Claim this Profile
S
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.
Nigel Russell, Jad Othman, Oliver Cumming, Abin Thomas, Aditya Tedjaseputra, Steven Knapper

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
Niek G van der Maas, Dimitri Breems, Clara P W Klerk, Thomas Pabst, Patrycja Gradowska, Steven Knapper

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.
Charlotte K Brierley, Bon Ham Yip, Giulia Orlando, Jeremy Wen, Sean Wen, Steven Knapper

Nat Genet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.
Nicola Potter, Jelena Jovanovic, Adam Ivey, Jad Othman, Abin Thomas, Steven Knapper

Lancet Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.
Henry Wood, Jenny O'Nions, Wei Yee Chan, Albert Borg, Scott Veitch, Steven Knapper

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Nigel H Russell, Abin Thomas, Robert K Hills, Ian Thomas, Amanda Gilkes, Steven Knapper

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.
Melanie Varley, Joanne Euden, Richard Adams, Eleanor Barnes, Craig Bodman, Steven Knapper

BMJ Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Stratification in Older Intensively Treated Patients With AML.
Jurjen Versluis, Marlen Metzner, Ariel Wang, Patrycja Gradowska, Abin Thomas, Steven Knapper

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With and Mutations.
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dillon, Steven Knapper

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Steven Knapper

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Sylvie D Freeman, Abin Thomas, Ian Thomas, Robert K Hills, Paresh Vyas, Steven Knapper

Blood· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H Boucher, Aimee Jackson, Steven Knapper

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Jad Othman, Nicola Potter, Katya Mokretar, David Taussig, Anjum Khan, Steven Knapper

Leukemia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Steven Knapper

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Harry J Iland, Nigel Russell, Richard Dillon, Andre C Schuh, Aditya Tedjaseputra, Steven Knapper

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocytapheresis in the management of adults with acute myeloid leukaemia: A survey of AML treating centres highlighting variability in practice.
Julia Wolf, Ian Thomas, Simon Stanworth, Steven Knapper, James Griffin

Transfus Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Francis Mussai, Carmela De Santo, Paul Cheng, Ian F Thomas, Cono Ariti, Steven K Knapper

Br J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Mike Dennis, Ian F Thomas, Cono Ariti, Laura Upton, Alan K Burnett, Steven Knapper

Blood Adv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Richard A Salisbury, Natalia Curto-Garcia, Jennifer O'Sullivan, Frederick Chen, Paolo Polzella, Steven Knapper

Leukemia· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Francesca L Hogan, Victoria Williams, Steven Knapper

Curr Cancer Drug Targets· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Namrata Rastogi, Sarah Baker, Stephen Man, Robert A Uger, Mark Wong, Steven Knapper

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 ligand in acute myeloid leukemia: a simple test with deep implications.
Pierre Peterlin, Patrice Chevallier, Steven Knapper, Matthew Collin

Leuk Lymphoma· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Pau Montesinos, Gail J Roboz, Claude-Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Steven Knapper

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Duffy-null genotype and risk of infection.
Sophie E Legge, Rune H Christensen, Liselotte Petersen, Antonio F Pardiñas, Matthew Bracher-Smith, Steven Knapper

Hum Mol Genet· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis